Research

CURE’s 2019-2020 research initiative includes the following studies:

Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta

Douglas Graham, MD, PhD
Aflac Cancer Center Precision Medicine Program

Robert Castellino, MD
PPM1D in High-Risk, Non-SHH, Non-WNT Medulloblastoma

Deborah DeRyckere, PhD
TAM Kinases as Mediators of Chemoresistance in AML

Lubing Gu, MD
Dual Inhibition of MDM2 and XIAP for Treatment of Childhood Cancers

Lisa Ingerski, PhD
HRQOL Outcomes During Molecularly Targeted Therapy for Brain Tumors

Christopher Porter, MD
Targeting Siglec15 for the Treatment of Childhood Cancers

Erwin Van Meir, PhD
Negative Regulation of b1-Integrin Signaling by ADGRB1 in Medulloblastoma

Muxiang Zhou, MD
MYCN Inhibition as a Precision Therapy in MYCN-amplified Neuroblastoma

Alexandra Stevens, MD
A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)

Lisa L. Wang, MD
Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma

Joanna Yi, MD
Defining the Transcriptional Control of Pediatric AML to Find New Drugs

Frank M. Balis, MD
GD2 as a Circulating Biomarker and Clinical Trial Endpoint for Neuroblastoma

Michael Chorny, PhD
Combination Therapy of Neuroblastoma Using Co-drug Impregnated Nanocarriers

Timothy Olson, MD, PhD
Bone Marrow Niche Targets to Prevent Cancer in Shwachman Diamond Syndrome

Soheil Meshinchi, MD, PhD
PedAL Initiative

Oren Becher, MD
Unraveling Mechanisms of Resistance to ACVR1 Inhibitors to Treat DIPG

Estibaliz Lopez Rodrigo, MD
Lung Macrophage Synergy with L-MTP-PE to Target Metastatic Osteosarcoma.

Zhihong Chen, PhD
Leveraging MMR Deficiency for Effective Immunotherapy in Childhood High-Grade Glioma

Maria-Grazia Roncarolo, MD
Innovative Cell Therapy for Pediatric AML

Kathleen Sakamoto, MD, PhD
Niclosamide for Relapsed/Refractory Pediatric AML